RxDoctor Payments DataLook up a doctor →

Andrew Solomon, MD

Neurology · Burlington, VTNPI 1407091366

Payments from drug & device makers

$1,900,317in general payments, 2019–2025

Across 429 payments — averaging $4429.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$486K
  • Novartis$412K
  • Sanofi$389K
  • Janssen Research & Development, LLC$223K
  • Bristol Myers Squibb$156K
  • Roche Products Limited$76K
  • plus $158K from 14 others
$7,040in research payments, 2019–2025

Across 1 payment — averaging $7040.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$7K

What the payments were for

  • Consulting fees$70,05249%
  • Speaking & faculty fees$42,50730%
  • Travel & lodging$25,45518%
  • Food & beverage$3,2762%
  • Education$1,1571%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,900,317 in reported general payments places this provider in the 95th percentile of 41 neurology providers in Vermont.

See all neurology providers in Vermont

Medicare billing

Part B allowed, 2024
$20,334
Medicare patients
88
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab51$431,041
CopaxoneGlatiramer Acetate27$168,104
TecfideraDimethyl Fumarate15$131,905
Glatiramer Acetate29$109,027
Dalfampridine ErDalfampridine49$46,545
GlatopaGlatiramer Acetate28$45,777
MyrbetriqMirabegron13$5,135
Baclofen214$4,963
Gabapentin138$2,644
Tizanidine Hcl105$1,352
Modafinil24$1,282
Teriflunomide16$1,277
AmantadineAmantadine Hcl16$744
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$580
Levetiracetam12$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$5,696$131,90515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 neurology providers in Vermont.

Other neurology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →